Letter. Ceftriaxone drug alert: no longer for first line use in meningococcal sepsis.
Letter. Ceftriaxone drug alert: no longer for first line use in meningococcal sepsis.
Although UK and international high income country practice has been to recommend ceftriaxone or cefotaxime as first line therapy for the initial treatment of paediatric sepsis, the US FDA has issued an alert1 that has led to changes in the US label for ceftriaxone.2 Due to concerns regarding the potential for calcium chelation in vivo, ceftriaxone must no longer be administered within 48 h of the completion of infusions of calcium-containing solutions, including parenteral nutrition, regardless of whether the drugs are administered by different infusion catheters.1 2 In the UK, the current drug safety bulletin3 states that ceftriaxone must not be given simultaneously with calcium-containing infusions.
We would therefore like to update the antibiotic recommendation made in our meningococcal therapy guideline update published in the April 2007 issue of ADC4 as follows: "Cefotaxime should be used as the first line antibiotic in meningococcal sepsis due to the high incidence of calcium replacement requirement in severe disease. However, ceftriaxone may still be considered as first line therapy in children with clinical meningitis, and for continuation of sepsis therapy after the acute phase when calcium infusions are no longer required. Where children are admitted for observation following cefotaxime for suspected sepsis and are subsequently assessed as being well enough for discharge on ambulatory intravenous antibiotics, the antibiotic may be changed to ceftriaxone (where the once/day dose regimen may be of benefit) and the first dose administered 8 hours following the last dose of cefotaxime given, assuming no calcium containing infusions have been used or are planned". The Meningitis Research Foundation will be making appropriate changes to their educational literature.
184-185
Faust, S.N .
f97df780-9f9b-418e-b349-7adf63e150c1
Pollard, A.J .
f9934b6a-e702-4557-80ff-ca0e0852351f
Nadel, S.
3504007b-b6c5-4716-a0a4-a4c5461753ba
Ninis, N.
1ce069aa-f919-48a5-849f-18fe1f022c26
Levin, M.
3668029d-82f9-422c-8a69-42ccae2e88bf
February 2008
Faust, S.N .
f97df780-9f9b-418e-b349-7adf63e150c1
Pollard, A.J .
f9934b6a-e702-4557-80ff-ca0e0852351f
Nadel, S.
3504007b-b6c5-4716-a0a4-a4c5461753ba
Ninis, N.
1ce069aa-f919-48a5-849f-18fe1f022c26
Levin, M.
3668029d-82f9-422c-8a69-42ccae2e88bf
Faust, S.N ., Pollard, A.J ., Nadel, S., Ninis, N. and Levin, M.
(2008)
Letter. Ceftriaxone drug alert: no longer for first line use in meningococcal sepsis.
Archives of Disease in Childhood, 93 (2), .
Abstract
Although UK and international high income country practice has been to recommend ceftriaxone or cefotaxime as first line therapy for the initial treatment of paediatric sepsis, the US FDA has issued an alert1 that has led to changes in the US label for ceftriaxone.2 Due to concerns regarding the potential for calcium chelation in vivo, ceftriaxone must no longer be administered within 48 h of the completion of infusions of calcium-containing solutions, including parenteral nutrition, regardless of whether the drugs are administered by different infusion catheters.1 2 In the UK, the current drug safety bulletin3 states that ceftriaxone must not be given simultaneously with calcium-containing infusions.
We would therefore like to update the antibiotic recommendation made in our meningococcal therapy guideline update published in the April 2007 issue of ADC4 as follows: "Cefotaxime should be used as the first line antibiotic in meningococcal sepsis due to the high incidence of calcium replacement requirement in severe disease. However, ceftriaxone may still be considered as first line therapy in children with clinical meningitis, and for continuation of sepsis therapy after the acute phase when calcium infusions are no longer required. Where children are admitted for observation following cefotaxime for suspected sepsis and are subsequently assessed as being well enough for discharge on ambulatory intravenous antibiotics, the antibiotic may be changed to ceftriaxone (where the once/day dose regimen may be of benefit) and the first dose administered 8 hours following the last dose of cefotaxime given, assuming no calcium containing infusions have been used or are planned". The Meningitis Research Foundation will be making appropriate changes to their educational literature.
This record has no associated files available for download.
More information
Published date: February 2008
Identifiers
Local EPrints ID: 59294
URI: http://eprints.soton.ac.uk/id/eprint/59294
ISSN: 0003-9888
PURE UUID: da26bdc4-be75-4c39-ba57-73215d70d057
Catalogue record
Date deposited: 03 Sep 2008
Last modified: 09 Jan 2022 03:21
Export record
Contributors
Author:
A.J . Pollard
Author:
S. Nadel
Author:
N. Ninis
Author:
M. Levin
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics